TC Biopharm (Holdings) Plc (TCBP)

NASDAQ: TCBP · IEX Real-Time Price · USD
4.93
-0.04 (-0.74%)
Feb 2, 2023, 10:19 AM EST - Market open
-0.74%
Market Cap 3.93M
Revenue (ttm) 2.41M
Net Income (ttm) -16.56M
Shares Out 794.95K
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 70,276
Open 5.00
Previous Close 4.97
Day's Range 4.91 - 5.04
52-Week Range 2.81 - 175.00
Beta n/a
Analysts Buy
Price Target 255.00 (+5,069.27%)
Earnings Date n/a

About TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 2022
Employees 76
Stock Exchange NASDAQ
Ticker Symbol TCBP
Full Company Profile

Financial Performance

In 2021, TCBP's revenue was 1.98 million, a change of 0.00% compared to the previous year's 1.98 million. Losses were -13.58 million, 148.7% more than in 2020.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for TCBP stock is "Buy." The 12-month stock price forecast is $255.0, which is an increase of 5,069.27% from the latest price.

Price Target
$255.0
(5,069.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division

Will oversee expansion of U.S. FDA Clinical Tria ls EDINBURGH, Scotland , Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a cl...

3 days ago - PRNewsWire

TC BioPharm to Host Shareholder Update Call

Conference Call to be held on Monday, February 20 th, 2023 at 10:00 am ET EDINBURGH, Scotland , Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP)...

1 week ago - PRNewsWire

TC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

EDINBURGH, Scotland , Jan. 19, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), has received written notification from the listing quali...

2 weeks ago - PRNewsWire

TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology

Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings EDINBURGH, Scotland , Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Compan...

2 weeks ago - PRNewsWire

TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update

Dosed first three patients within Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML). Complete and near complete responses (m...

1 month ago - PRNewsWire

TC BioPharm Announces Closing of $7.35 Million Private Placement

EDINBURGH, Scotland , Nov. 30, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company developing platfo...

2 months ago - PRNewsWire

TC BioPharm Announces $7.35 Million Private Placement

EDINBURGH, Scotland , Nov. 28, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (Nasdaq: TCBP) (Nasdaq: TCBPW), a clinical stage biotechnology company developing platfo...

2 months ago - PRNewsWire

TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia

3 Patients Dosed in 5 Patient Safety Cohort EDINBURGH, Scotland , Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical s...

2 months ago - PRNewsWire

TC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy Expertise

SAB selected to advance new therapeutic trials and strategic partnerships EDINBURGH, Scotland , Oct. 26, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP)...

3 months ago - PRNewsWire

TC BioPharm to Present at Upcoming Investor Conferences

EDINBURGH, Scotland , Oct. 3, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

4 months ago - PRNewsWire

TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®

EDINBURGH, Scotland , Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platf...

5 months ago - PRNewsWire

TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

EDINBURGH, Scotland , Aug. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfo...

5 months ago - PRNewsWire

TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit

Event Taking Place in Boston on July 26-28, 2022 EDINBURGH, Scotland , July 25, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clini...

6 months ago - PRNewsWire

TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"

Management will Participate in Fireside Chat on TC BioPharm's Journey as a Successful CGT Startup on July 13, 2022 EDINBURGH, Scotland., July 8, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Bi...

7 months ago - PRNewsWire

TC Biopharm Announces Closing of $4 Million Underwritten Public Offering

EDINBURGH, Scotland , June 7, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

8 months ago - PRNewsWire

TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering

EDINBURGH, Scotland , June 2, 2022 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

8 months ago - PRNewsWire

TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally

EDINBURGH, Scotland , May 31, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platfor...

8 months ago - PRNewsWire

Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market

Sector is Expected to Surpass $4 Billion by 2028 Report Highlights Promising Therapy and Rising Investment from Pharmaceutical Companies EDINBURGH, Scotland , May 23, 2022 /PRNewswire/ -- TC Biopharm ...

9 months ago - PRNewsWire

TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts

Dr. Mark Bonyhadi to spearhead SAB EDINBURGH, Scotland, May 18, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotec...

9 months ago - PRNewsWire

TC BioPharm Invited to Present at LD Micro Conference

EDINBURGH, Scotland , May 3, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform...

9 months ago - PRNewsWire

TC BioPharm to Participate in Upcoming Conferences

EDINBURGH, Scotland , April 26, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platf...

10 months ago - PRNewsWire

TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML Day

EDINBURGH, Scotland , April 21, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platf...

10 months ago - PRNewsWire

TC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing Process

6-month shelf-life milestone achieved Successful thaw of highly activated Gamma delta cells EDINBURGH, Scotland , April 6, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Compan...

10 months ago - PRNewsWire

TC BioPharm Announces Initiation of Equity Analyst Coverage by EF Hutton with a "Buy" Recommendation

EDINBURGH, Scotland , March 29, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platf...

11 months ago - PRNewsWire

TC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Treatment of Acute Myeloid Leukemia

Trial enrollment expected to begin during the first half of 2022 EDINBURGH, Scotland , March 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ...

11 months ago - PRNewsWire